231 related articles for article (PubMed ID: 9692972)
1. Camptothecins inhibit the utilization of hydrogen peroxide in the ligation step of topoisomerase I catalysis.
Lisby M; Krogh BO; Boege F; Westergaard O; Knudsen BR
Biochemistry; 1998 Jul; 37(30):10815-27. PubMed ID: 9692972
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification.
Wang X; Wang LK; Kingsbury WD; Johnson RK; Hecht SM
Biochemistry; 1998 Jun; 37(26):9399-408. PubMed ID: 9649322
[TBL] [Abstract][Full Text] [Related]
3. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
[TBL] [Abstract][Full Text] [Related]
4. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
Jaxel C; Kohn KW; Wani MC; Wall ME; Pommier Y
Cancer Res; 1989 Mar; 49(6):1465-9. PubMed ID: 2538227
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase I-mediated formation of structurally modified DNA duplexes. Effects of metal ions and topoisomerase I inhibitors.
Wang X; Henningfeld KA; Hecht SM
Biochemistry; 1998 Feb; 37(8):2691-700. PubMed ID: 9485420
[TBL] [Abstract][Full Text] [Related]
7. Peptide inhibitors of DNA cleavage by tyrosine recombinases and topoisomerases.
Klemm M; Cheng C; Cassell G; Shuman S; Segall AM
J Mol Biol; 2000 Jun; 299(5):1203-16. PubMed ID: 10873446
[TBL] [Abstract][Full Text] [Related]
8. Water-soluble camptothecin derivatives that are intrinsic topoisomerase I poisons.
Rahier NJ; Eisenhauer BM; Gao R; Jones SH; Hecht SM
Org Lett; 2004 Feb; 6(3):321-4. PubMed ID: 14748583
[TBL] [Abstract][Full Text] [Related]
9. The effect of camptothecin on topoisomerase I catalysis.
Christiansen K; Westergaard O
Ann N Y Acad Sci; 1996 Dec; 803():50-9. PubMed ID: 8993500
[TBL] [Abstract][Full Text] [Related]
10. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
11. Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity.
Habermeyer M; Fritz J; Barthelmes HU; Christensen MO; Larsen MK; Boege F; Marko D
Chem Res Toxicol; 2005 Sep; 18(9):1395-404. PubMed ID: 16167831
[TBL] [Abstract][Full Text] [Related]
12. Conjugated eicosapentaenoic acid inhibits human topoisomerase IB with a mechanism different from camptothecin.
Castelli S; Campagna A; Vassallo O; Tesauro C; Fiorani P; Tagliatesta P; Oteri F; Falconi M; Majumder HK; Desideri A
Arch Biochem Biophys; 2009 Jun; 486(2):103-10. PubMed ID: 19397888
[TBL] [Abstract][Full Text] [Related]
13. The dihydropyridine dexniguldipine hydrochloride inhibits cleavage and religation reactions of eukaryotic DNA topoisomerase I.
Straub T; Boesenberg C; Gekeler V; Boege F
Biochemistry; 1997 Sep; 36(35):10777-83. PubMed ID: 9271509
[TBL] [Abstract][Full Text] [Related]
14. The covalent eukaryotic topoisomerase I-DNA intermediate catalyzes pH-dependent hydrolysis and alcoholysis.
Christiansen K; Knudsen BR; Westergaard O
J Biol Chem; 1994 Apr; 269(15):11367-73. PubMed ID: 8157668
[TBL] [Abstract][Full Text] [Related]
15. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
[TBL] [Abstract][Full Text] [Related]
16. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
17. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Danks MK; Pawlik CA; Whipple DO; Wolverton JS
Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
[TBL] [Abstract][Full Text] [Related]
18. Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I.
Das BB; Sen N; Roy A; Dasgupta SB; Ganguly A; Mohanta BC; Dinda B; Majumder HK
Nucleic Acids Res; 2006; 34(4):1121-32. PubMed ID: 16488884
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of camptothecin resistance by human topoisomerase I mutations.
Chrencik JE; Staker BL; Burgin AB; Pourquier P; Pommier Y; Stewart L; Redinbo MR
J Mol Biol; 2004 Jun; 339(4):773-84. PubMed ID: 15165849
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of topoisomerase I function by coralyne and 5,6-dihydrocoralyne.
Wang LK; Rogers BD; Hecht SM
Chem Res Toxicol; 1996; 9(1):75-83. PubMed ID: 8924619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]